Cinctive Capital Management LP Acquires New Holdings in IQVIA Holdings Inc. $IQV

Cinctive Capital Management LP bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 13,214 shares of the medical research company’s stock, valued at approximately $2,510,000.

Other hedge funds also recently modified their holdings of the company. Brighton Jones LLC lifted its position in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after acquiring an additional 2,537 shares during the period. Empowered Funds LLC boosted its position in IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after buying an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in IQVIA during the 2nd quarter worth approximately $514,000. Allworth Financial LP grew its holdings in shares of IQVIA by 43.3% during the second quarter. Allworth Financial LP now owns 970 shares of the medical research company’s stock worth $153,000 after purchasing an additional 293 shares during the last quarter. Finally, Vise Technologies Inc. bought a new stake in IQVIA during the 2nd quarter worth about $286,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on IQV shares. Morgan Stanley set a $240.00 price objective on IQVIA in a research report on Wednesday, February 11th. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Citigroup dropped their price target on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Finally, Royal Bank Of Canada began coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Buy” and an average price target of $229.13.

IQVIA Stock Up 0.1%

IQV opened at $164.90 on Tuesday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The company has a market capitalization of $27.98 billion, a P/E ratio of 20.98, a P/E/G ratio of 1.59 and a beta of 1.40. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The stock has a fifty day moving average of $200.18 and a 200-day moving average of $206.76.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same quarter in the prior year, the business posted $3.12 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.